-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entering 2022, the pharmaceutical industry at home and abroad is still surging, and it is very lively
.
Not long after the opening in January, a group of pharmaceutical companies staged a big drama of marriage and breakup, involving local pharmaceutical companies such as Wuzhong Medicine and Betta Pharmaceuticals, as well as multinational companies such as Sanofi and Daiichi Sankyo
.
A group of pharmaceutical companies "break up" Soon after the beginning of the new year, a group of pharmaceutical companies reported "breakup" news
.
For example, in China, Wu Chinese Medicine recently issued an announcement on the termination of the equity acquisition intention agreement
.
The announcement stated that previously, the company signed the "Equity Acquisition Intention Agreement" with Weina Hong Kong and Shanghai Weina.
Weina Hong Kong now holds 100% equity of Shanghai Weina, and the company or the company's wholly-owned subsidiary intends to acquire a lot of Shanghai Weina.
at 70% of the equity
.
However, during the due diligence period, the company found that there was an unresolved litigation dispute between Vina Hong Kong Co.
, Ltd.
and Li Shanyong.
In order to protect the legitimate rights and interests of the company, the company requested the other party to make a true, complete and accurate explanation to the company on the above incident, and to express apology and Compensation for the direct economic losses arising from the acquisition
.
Because the other party failed to make any response within the stipulated time limit, it did not explain or apologize to the company
.
In this regard, Jiangsu Wuzhong Medicine has made a decision to terminate the acquisition
.
It is understood that the "hand in hand" between the two companies will start from September 28, 2021.
At that time, Jiangsu Wuzhong established a development strategy and industrial layout with "pharmaceutical + medical beauty" as the company's core business.
Or the company's wholly-owned subsidiary has made a decision to acquire no less than 70% equity of Shanghai Vina, whose main business is the research and development and production of cosmetic products, in order to hope to use the latter's sales network and channels to rapidly develop medical beauty.
Industrial layout
.
Among them, the tentative consideration for the acquisition of the shares by both parties is approximately RMB 700 million
.
However, this "hand in hand" lasted less than half a year, and Wu TCM terminated the acquisition cooperation
.
In terms of foreign pharmaceutical companies, such as Sanofi recently announced that it will terminate the cooperation transaction with Sangamo, abandon the personalized cell therapy, and shift the research and development focus to the allogeneic universal genomic medicine method.
.
It is reported that the termination of the cooperation transaction between the two parties will officially take effect on June 28, 2022, and Sanofi will return full control of the sickle cell disease candidate drug SAR445136 to Sangamo
.
Some analysts believe that the reason for Sanofi's withdrawal from cooperation may be because the sickle cell disease track is becoming increasingly fierce
.
A group of pharmaceutical companies "marriage" While a group of pharmaceutical companies "break up", there are also a number of pharmaceutical companies that have opened a strong cooperation model, which is worthy of attention
.
For example, on January 23, Betta Pharmaceuticals announced that the company's wholly-owned subsidiary, Betta Biopharmaceuticals, planned to invest 76 million yuan to acquire Zhejiang Shimai Pharmaceutical Co.
, Ltd.
held by Ningbo Kaiming Investment Management Partnership (Limited Partnership).
The capital contribution of RMB 628,772 is 3.
4081% equity
.
The company said that the transfer of equity will be beneficial to Betta Pharmaceuticals' layout in the field of antibody drugs
.
According to the data, Shimai Pharmaceutical is an innovative enterprise in the research and development of targeted antibody drugs for malignant tumors and autoimmune diseases
.
On January 7, Hainan Shuangcheng Pharmaceutical announced that it agreed to the company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
to plan to own specific intellectual property rights and production related to memantine hydrochloride tablets (5mg, 10mg) for 6 million yuan.
The rights of the technology in the designated area are granted to Baishan Pharmaceutical (Huzhou) Co.
,
Ltd.
.
Not long after the opening in January, a group of pharmaceutical companies staged a big drama of marriage and breakup, involving local pharmaceutical companies such as Wuzhong Medicine and Betta Pharmaceuticals, as well as multinational companies such as Sanofi and Daiichi Sankyo
.
A group of pharmaceutical companies "break up" Soon after the beginning of the new year, a group of pharmaceutical companies reported "breakup" news
.
For example, in China, Wu Chinese Medicine recently issued an announcement on the termination of the equity acquisition intention agreement
.
The announcement stated that previously, the company signed the "Equity Acquisition Intention Agreement" with Weina Hong Kong and Shanghai Weina.
Weina Hong Kong now holds 100% equity of Shanghai Weina, and the company or the company's wholly-owned subsidiary intends to acquire a lot of Shanghai Weina.
at 70% of the equity
.
However, during the due diligence period, the company found that there was an unresolved litigation dispute between Vina Hong Kong Co.
, Ltd.
and Li Shanyong.
In order to protect the legitimate rights and interests of the company, the company requested the other party to make a true, complete and accurate explanation to the company on the above incident, and to express apology and Compensation for the direct economic losses arising from the acquisition
.
Because the other party failed to make any response within the stipulated time limit, it did not explain or apologize to the company
.
In this regard, Jiangsu Wuzhong Medicine has made a decision to terminate the acquisition
.
It is understood that the "hand in hand" between the two companies will start from September 28, 2021.
At that time, Jiangsu Wuzhong established a development strategy and industrial layout with "pharmaceutical + medical beauty" as the company's core business.
Or the company's wholly-owned subsidiary has made a decision to acquire no less than 70% equity of Shanghai Vina, whose main business is the research and development and production of cosmetic products, in order to hope to use the latter's sales network and channels to rapidly develop medical beauty.
Industrial layout
.
Among them, the tentative consideration for the acquisition of the shares by both parties is approximately RMB 700 million
.
However, this "hand in hand" lasted less than half a year, and Wu TCM terminated the acquisition cooperation
.
In terms of foreign pharmaceutical companies, such as Sanofi recently announced that it will terminate the cooperation transaction with Sangamo, abandon the personalized cell therapy, and shift the research and development focus to the allogeneic universal genomic medicine method.
.
It is reported that the termination of the cooperation transaction between the two parties will officially take effect on June 28, 2022, and Sanofi will return full control of the sickle cell disease candidate drug SAR445136 to Sangamo
.
Some analysts believe that the reason for Sanofi's withdrawal from cooperation may be because the sickle cell disease track is becoming increasingly fierce
.
A group of pharmaceutical companies "marriage" While a group of pharmaceutical companies "break up", there are also a number of pharmaceutical companies that have opened a strong cooperation model, which is worthy of attention
.
For example, on January 23, Betta Pharmaceuticals announced that the company's wholly-owned subsidiary, Betta Biopharmaceuticals, planned to invest 76 million yuan to acquire Zhejiang Shimai Pharmaceutical Co.
, Ltd.
held by Ningbo Kaiming Investment Management Partnership (Limited Partnership).
The capital contribution of RMB 628,772 is 3.
4081% equity
.
The company said that the transfer of equity will be beneficial to Betta Pharmaceuticals' layout in the field of antibody drugs
.
According to the data, Shimai Pharmaceutical is an innovative enterprise in the research and development of targeted antibody drugs for malignant tumors and autoimmune diseases
.
On January 7, Hainan Shuangcheng Pharmaceutical announced that it agreed to the company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
to plan to own specific intellectual property rights and production related to memantine hydrochloride tablets (5mg, 10mg) for 6 million yuan.
The rights of the technology in the designated area are granted to Baishan Pharmaceutical (Huzhou) Co.
,
Ltd.
